Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026
Rhea-AI Summary
Vaxart (OTCQX: VXRT) will present at the virtual Global BioInnovation Forum on Tuesday, January 13, 2026. Senior leaders speaking are Steven Lo (CEO), Sean Tucker, Ph.D. (Founder & Chief Scientific Officer) and James F. Cummings, M.D. (Chief Medical Officer).
The presentation is scheduled for 11:30am PT / 2:30pm ET. A live webcast will be available via the company's investor relations website and will remain accessible for 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – VXRT
In the Jan 9 session, VXRT gained 41.70%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 13 | Earnings & update | Positive | +11.0% | Q3 2025 results plus Dynavax collaboration and COVID-19 trial milestones. |
| Nov 07 | Investor webcasts | Positive | +7.2% | Announcement of Q3 earnings call and stockholder fireside chat. |
| Oct 20 | Conference presentation | Positive | -1.4% | Phase 1 data on second-generation norovirus oral pill vaccine at IDWeek 2025. |
| Oct 08 | Program showcase | Positive | -2.2% | Showcase of norovirus and COVID-19 oral pill vaccines at World Vaccine Congress. |
| Sep 19 | Corporate action | Positive | +0.6% | Withdrawal of reverse stock split proposal after shareholder feedback. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
VXRT has often reacted positively to earnings and investor communication, while some conference/showcase events have seen weaker or negative follow-through.
Over the last few months, Vaxart’s news flow has centered on financial results, investor communications, scientific presentations, and capital structure decisions. The Q3 2025-11-13 earnings and Dynavax collaboration update coincided with a +10.96% move, while a 2025-11-07 webcast announcement saw a +7.19% reaction. In contrast, conference presentations in October 2025 drew modest negative moves. The withdrawal of a reverse stock split proposal on 2025-09-19 had a small positive impact, showing mixed sensitivity to non-clinical, communication-focused catalysts.
Key Terms
recombinant medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart or “the Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will participate in the Global BioInnovation Forum, a virtual gathering of senior leaders building and scaling next-generation life science and health innovation companies.
Presentation Details:
Speakers: Steven Lo, Chief Executive Officer, Sean Tucker, Ph.D., Founder and Chief Scientific Officer, and James F. Cummings, M.D., Chief Medical Officer
Date: Tuesday, January 13, 2026
Time: 11:30am PT, 2:30pm ET
Registration and Webcast: Click Here
The webcast will be available on the Company’s investor relations website at https://investors.vaxart.com for 30 days following the conclusion of the event.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact:
Vaxart Media and Investor Relations:
FINN Partners
IR@vaxart.com
